Methotrexate suppresses NF-κB activation through inhibition of IκBα phosphorylation and degradation

Journal of Immunology

Volumn 167, Issue 5, 2001, Pages 2911-2920

  Majumdar, S ^a   Aggarwal, B B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ANTIINFLAMMATORY AGENT; FOLIC ACID ANTAGONIST; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; METHOTREXATE; TUMOR NECROSIS FACTOR;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFLAMMATION; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REPORTER GENE;

EID: 0035451439     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.5.2911     Document Type: Article

References (56)

1. The mechanism of action of methotrexate
2. Molecular and cellular effects of methotrexate
3. Long-term prospective study of methotrexate in rheumatoid arthritis: Conclusion after 132 months of therapy
4. FK506 combination with methotrexate for the prevention of graft-vs-host disease after marrow transplantation from matched unrelated donors
5. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease: North American Crohn's study group investigators
6. Mechanisms of action of methotrexate
7. Polyglutamation of methotrexate: Is methotrexate a prodrug?
8. Effects of methotrexate on nucleotide pools in normal human T cells and the CEM T cell line
9. 1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage
10. Immunosuppressive properties of methotrexate: Apoptosis and clonal deletion of activated peripheral T cells
11. Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: A metabolic basis for efficacy in rheumatoid arthritis?
12. Anti-inflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: Evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction
13. Methotrexate suppresses the interleukin-6 induced generation of reactive oxygen species in the synoviocytes of rheumatoid arthritis
14. Effects of methotrexate on differentiation of monocytes and production of cytokine inhibitors by monocytes
15. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5′nucleotidase-mediated conversion of adenine nucleotides
16. Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: Evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis
17. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis: Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers
18. Increased adenosine concentration in blood from ischemic myocardium by AICA-fiboside: Effects on flow granulocytes and injury
19. Selective adenosine release from human B but not T lymphoid cell line
20. Inhibition of TNF expression by adenosine: Role of A3 adenosine receptors
21. Differential regulatory effects of adenosine on cytokine release by activated human monocytes
22. The antiinflammatory effects of methotrexate are mediated by adenosine
23. Rel/NF-κB/IκB family: Intimate tales of association and dissociation
24. Activation of the transcription factor nuclear factor-κB in human inflamed synovial tissue
25. Cell-specific effects of glucocorticoid treatment on the NFκB p65/IκBα system in patients with Crohn's disease
26. NF-κB as a frequent target for immunosuppressive and anti-inflammatory molecules
27. Assay for redox-sensitive transcription factors
28. Human chorionic gonadotropin suppresses activation of nuclear transcription factor-κB and activator protein-1 induced by tumor necrosis factor
29. Leflunomide suppresses TNF-induced cellular responses: Effects on NF-κB, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis
30. Activation of NF-κB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-κB-inducing kinase: Identification of a novel TRAF6 interaction motif
31. Inducible phosphorylation of IκBα is not sufficient for its dissociation from NF-κB and is inhibited by protease inhibitors
32. Studies into the effect of the tyrosine kinase inhibitor herbimycin A on NF-κB activation in T lymphocytes: Evidence for covalent modification of the p50 subunit
33. Caffeic acid phenethyl ester (CAPE) is a potent and specific inhibitor of activation of nuclear transcription factor NF-κB
34. Distinct signal transduction pathways mediate nuclear factor-κB induction by IL-1β in epithelial and lymphoid cells
35. Oxidative stress induces NF-κB nuclear translocation without degradation of IκBα
36. IκBα degradation is not a requirement for the X-ray-induced activation of nuclear factor κB in normal rat astrocytes and human brain tumour cells
37. Ischemia/reperfusion injury in the liver of BALB/c mice activates AP-1 and nuclear factor κB independently of IκB degradation
38. Pervanadate-induced nuclear factor-κB activation requires tyrosine phosphorylation and degradation of IκB α: Comparison with tumor necrosis factor-α
39. Differential IκB kinase activation and IκKBα degradation by interleukin-1β and tumor necrosis factor-α in human U937 monocytic cells: Evidence for additional regulatory steps in κB-dependent transcription
40. Ionizing radiation and short wavelength UV activate NF-κB through two distinct mechanisms
41. Activation of transcription factor NF-κB is suppressed by curcumin (diferulolylmethane)
42. Oleandrin suppresses activation of nuclear transcription factor-κB, activator protein-1, and c-Jun N-terminal kinase
43. Silymarin suppresses TNF-induced activation of nuclear transcription factor-κB, c-Jun N-terminal kinase, and apoptosis
44. Inhibition of interleukin-1-stimulated NF-κB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity
45. Phosphorylation meets ubiquitination: The control of NF-κB activity
46. Cytokine blockade as a new strategy to treat rheumatoid arthritis: Inhibition of tumor necrosis factor
47. Activators and target genes of Rel/NF-κB transcription factors
48. Inhibition of TNF expression by adenosine: Role of A3 adenosine receptors
49. Functional characterization of A2 receptors in Jurkat cells and PCl2 cells using adenosine receptor agonists
50. Expression of A2B adenosine receptors in human lymphocytes: Their role in T cell activation
51. 5′-nucleotidase: Molecular structure and functional aspects
52. Tissue-specific regulation of the ecto-5′-nucleotidase promoter: Role of the cAMP response element site in mediating repression by the upstream regulatory region
53. Selective induction of CD73 expression in human lymphocytes by CD38 ligation: A novel pathway linking signal transducers with ecto-enzyme activities
54. Activation of transcription factor NF-κB in human synovial cells in response to tumor necrosis factor α
55. Nuclear factor KB (NF-κB) pathway as a therapeutic target in rheumatoid arthritis
56. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-κB activation and gene expression